论坛 › 天涯交友 › 会后报告 | PIC 2021 第二届药物研发热点技术与平台论坛圆满落幕

nqkk58 发表于 2024-6-24 13:13:08

会后报告 | PIC 2021 第二届药物研发热点技术与平台论坛圆满落幕

    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">内容列表样式</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">内容列表样式</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">内容列表样式</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">2021年9月28日--中国上海，为期两天的</span><span style="color: black;"><strong style="color: blue;">PIC 2021 第二届<span style="color: black;">药品</span><span style="color: black;">开发</span>热点技术与平台论坛</strong></span><span style="color: black;">圆满落幕。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/Ivoyg91aXs2pibcQ6Pcegicq1pkbfKNdbUEeRt8zlnTpRk2vEqMe4ia6Q5M7OM8zUjMWsicKeI3IIFEa9OZADBV5gw/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">多位国内外知名医药行业领袖、新药<span style="color: black;">开发</span>的先行者与实践者、生物药及化学药行业的<span style="color: black;">公司</span>家与专家，<span style="color: black;">一起</span>探索国内<span style="color: black;">药品</span><span style="color: black;">研发</span>新方向！</span></p><span style="color: black;"><strong style="color: blue;">PIC 2021</strong></span><span style="color: black;"><strong style="color: blue;">嘉宾集锦</strong></span><span style="color: black;">
      <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">为期两天的会议中，致力于新型抗体、ADC、NASH新药、小分子新药<span style="color: black;">研发</span>以及<span style="color: black;">解决</span>不可成药靶点的<span style="color: black;">开发</span><span style="color: black;">公司</span>与<span style="color: black;">公司</span>、<span style="color: black;">研究</span>院所及投资<span style="color: black;">公司</span>等各方带来了34场精彩的讲演以及4场圆桌讨论。</p>
    </span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">主会场：</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">公司</span>家战略与合作峰会</strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/Ivoyg91aXs0q6R5qUDqMSrFOficKrsn6fIr6jzk47gNOLM7uN6E1OkoNbQnh1s3uofMVPC9ydEibHeC9S5XIGr2w/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">糖尿病市场在过去十年里高速增长。2019年，<span style="color: black;">全世界</span>范围内，与糖尿病<span style="color: black;">关联</span>的花费约为7600亿美元；中国范围内，与糖尿病<span style="color: black;">关联</span>的花费约为1090亿美元，市场<span style="color: black;">潜能</span>巨大。</span><strong style="color: blue;"><span style="color: black;">华领医</span><span style="color: black;">药副总裁营销战略与市场部&nbsp;徐文洁</span></strong><span style="color: black;">以旗下糖尿病首创新药多扎格列艾汀的两项临床<span style="color: black;">科研</span>案例为切入点，为行业同仁们<span style="color: black;">供给</span>了以临床价值为导向的糖尿病<span style="color: black;">药物</span>创新思路。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/Ivoyg91aXs0q6R5qUDqMSrFOficKrsn6fdco7ATJ8erK6a8oEicX8OBzUIlFgFKrqt3lZyYF8akicicIp6NZuhiao9Q/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">鸿运华宁（杭州）生物医药有限<span style="color: black;">机构</span>高级副总裁&amp;首席科学官&nbsp;张成博士</span></strong><span style="color: black;">基于<span style="color: black;">数年</span>的GPCR抗体新药<span style="color: black;">研发</span>经验，为<span style="color: black;">大众</span>分享了治疗肺动脉高压 (PAH) 抗体最新<span style="color: black;">发展</span>，以及鸿运华宁独特的M-Body技术平台。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/Ivoyg91aXs0q6R5qUDqMSrFOficKrsn6fzddkibu2hPdeREzHVyicjozbzWwycvwtr7pOib1baXdiaOefwqYQXkAODA/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">药明康德高级<span style="color: black;">专家</span> HitS事业部抗体负责人&nbsp;<strong style="color: blue;"><span style="color: black;">王鹏博士</span></strong></span></strong><span style="color: black;"><span style="color: black;">发布</span>了题为生物分析<span style="color: black;">重要</span>试剂在生物药<span style="color: black;">开发</span>中的应用的演讲。药明康德HitS事业部为<span style="color: black;">全世界</span><span style="color: black;">药品</span><span style="color: black;">开发</span>行业<span style="color: black;">供给</span><span style="color: black;">拥有</span>竞争力的一体化靶标到苗头化合物<span style="color: black;">发掘</span><span style="color: black;">处理</span><span style="color: black;">方法</span>。本着以<span style="color: black;">科研</span>为首任，以客户为中心的宗旨，药明康德HitS事业部<span style="color: black;">经过</span>高质量和个性化的<span style="color: black;">开发</span>服务，助力客户<span style="color: black;">提高</span>苗头化合物<span style="color: black;">研发</span>效率，服务范围涵盖蛋白科学、抗体科学、DNA编码化合物库技术、生物<span style="color: black;">理学</span>学、结构生物学<span style="color: black;">科研</span>等<span style="color: black;">行业</span>。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/Ivoyg91aXs0q6R5qUDqMSrFOficKrsn6fkK5HGK5dMgcdGQicPaG7xPEn5wqMlk0kwexgUBT5DFnrBhDygtALGOg/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">聚焦<strong style="color: blue;">中国新药创新的战略规划与布局</strong>的圆桌环节，由<strong style="color: blue;"><span style="color: black;">前辉瑞<span style="color: black;">全世界</span><span style="color: black;">开发</span>副总裁&nbsp;</span><span style="color: black;">尹鹤群博士</span></strong><span style="color: black;">担任圆桌主持人。</span><strong style="color: blue;"><span style="color: black;">英诺湖医药创始人、董事长&amp;首席执行官&nbsp;夏明德博士</span></strong><span style="color: black;">、<strong style="color: blue;">百时美施贵宝<span style="color: black;">全世界</span><span style="color: black;">药品</span><span style="color: black;">开发</span>中国综合科学团队执行总监&nbsp;边峰博士</strong>、<strong style="color: blue;">苏州沃生生物医药有限<span style="color: black;">机构</span>创始人&amp;CEO 孙巾荃博士</strong>与<strong style="color: blue;">亚盛医药 CMC Head &amp; 高级副总经理&nbsp;温剑锋博士</strong><span style="color: black;">一起</span>参与讨论。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/Ivoyg91aXs0q6R5qUDqMSrFOficKrsn6fvIceWluPvsXtLISr9ofhViccVSVIjwQTCiaAc1kyevLFqsiadbBO4ngRw/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">聚焦<strong style="color: blue;">不同路径下的<span style="color: black;">药品</span><span style="color: black;">研发</span>&amp;估值、投资</strong>的圆桌环节，由<strong style="color: blue;"><span style="color: black;">睿诺医疗科技(上海)有限<span style="color: black;">机构</span>总经理/创始人</span><span style="color: black;">马法书博士</span></strong><span style="color: black;">担任圆桌主持人。</span><strong style="color: blue;"><span style="color: black;">礼来亚洲基金<span style="color: black;">危害</span>合伙人&nbsp;李彬博士</span></strong><span style="color: black;">、<strong style="color: blue;">维亚生物首席商务官&amp;投资负责人&nbsp;戴晗博士</strong>、<strong style="color: blue;">再鼎医药<span style="color: black;">科研</span>及<span style="color: black;">研发</span>首席运营官 阎水忠博士</strong>、<strong style="color: blue;">英派药业EVP 蔡遂雄博士</strong>与<strong style="color: blue;">康希诺生物股份<span style="color: black;">机构</span>联合创始人&amp;高级副总 商务发展&nbsp;邱东旭博士</strong><span style="color: black;">一起</span>参与<span style="color: black;">这次</span>讨论。</span></span></p><span style="color: black;"><strong style="color: blue;"><span style="color: black;">分会场：</span></strong></span><span style="color: black;"><strong style="color: blue;">新型抗体<span style="color: black;">研发</span></strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/Ivoyg91aXs0q6R5qUDqMSrFOficKrsn6fFxkxRL6f8VGrhnX168ibNQkPjYlbYb1fhXza52iaascb7PyTSsFAryAQ/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">百奥赛图新药<span style="color: black;">科研</span>院开发三部总监&nbsp;杨勇飞博士</span></strong><span style="color: black;">介绍了RenLite全人<span style="color: black;">一起</span>轻链抗体小鼠这一双特异性抗体新药<span style="color: black;">研发</span>利器。百奥赛图是一家创新技术驱动新药<span style="color: black;">开发</span>的国际性生物技术<span style="color: black;">机构</span>，致力于<span style="color: black;">作为</span><span style="color: black;">全世界</span>新药发源地，以专注技术创新、<span style="color: black;">连续</span>新药产出、<span style="color: black;">保护</span>人类健康为使命。随着规模化抗体<span style="color: black;">药品</span><span style="color: black;">开发</span>-“千鼠万抗TM”计划的实施，百奥赛图将携手<span style="color: black;">全世界</span>合作伙伴，<span style="color: black;">一起</span>加速新药<span style="color: black;">开发</span>。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/Ivoyg91aXs0q6R5qUDqMSrFOficKrsn6fjiarn0y5TkgtWhUZlcia8DxrOVjVGvdvrMnHwh6kLvH689nxHgt1cRdg/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">艾美斐生物创始人、董事长&amp;首席执行官&nbsp;<strong style="color: blue;"><span style="color: black;">范国煌博士</span></strong></span></strong><span style="color: black;"><span style="color: black;">发布</span>了题为Targeting tumor microenvironment for anti-cancer drug discovery的演讲，分享了范博士<span style="color: black;">这里</span>方面的深刻见解。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/Ivoyg91aXs0q6R5qUDqMSrFOficKrsn6fFxF19O6uHRrFKBJskAXZjbsEicSPhL7s2Q1VFuQ38BsuYODcZHWsicBw/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">北京大橡科技有限<span style="color: black;">机构</span>联合创始人兼首席<span style="color: black;">专家</span>&nbsp;<span style="color: black;">艾晓妮博士</span></span></strong>针对类器官芯片在<span style="color: black;">药品</span><span style="color: black;">开发</span>中的应用这一<span style="color: black;">专题</span>进行了深度分享。<span style="color: black;">北京大橡科技有限<span style="color: black;">机构</span>是中国领先的<span style="color: black;">开发</span>和生产人体器官芯片和类器官芯片的高科技<span style="color: black;">机构</span>，致力于推动和引领器官芯片和类器官芯片在新药<span style="color: black;">开发</span>、<span style="color: black;">疾患</span>建模和个体化<span style="color: black;">精细</span>医疗等<span style="color: black;">行业</span>的广泛应用，以更<span style="color: black;">精细</span>、更<span style="color: black;">有效</span>、更经济的<span style="color: black;">药品</span><span style="color: black;">开发</span><span style="color: black;">处理</span><span style="color: black;">方法</span>和创新、仿生的临床<span style="color: black;">精细</span>用药标准化平台，实现“用创新的器官芯片技术构建健康世界”的<span style="color: black;">公司</span>愿景。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/Ivoyg91aXs0q6R5qUDqMSrFOficKrsn6fJJ0cqgicObwtjOvmCPJQ6Wlvf9ysOnneau8dAngGhYrtLgpsPbLtuvQ/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">生物岛实验室<span style="color: black;">科研</span>员，天勤生物“基因修饰小鼠模型”合作<span style="color: black;">专家</span>&nbsp;<strong style="color: blue;"><span style="color: black;">吴光明</span></strong><strong style="color: blue;"><span style="color: black;">博士</span></strong></span></strong><span style="color: black;">向行业同仁们介绍了利用颠覆性的四倍体技术来快速制备小鼠动物模型及其在创新<span style="color: black;">药品</span><span style="color: black;">开发</span>方面的工作。湖北天勤生物科技是一家以大动物<span style="color: black;">实验</span>为<span style="color: black;">特殊</span>的非临床新药<span style="color: black;">科研</span>与<span style="color: black;">评估</span>CRO高新技术<span style="color: black;">公司</span>。<span style="color: black;">机构</span>以非人灵长类实验动物繁育、人类<span style="color: black;">疾患</span>动物模型<span style="color: black;">开发</span>、<span style="color: black;">药品</span>毒性及安全性<span style="color: black;">评估</span>、药代动力学与药效学、分子影像检测、生物分析和生物统计为核心业务，服务医药创新，致力生命健康，是产学研一体化的生物医药公共服务平台。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/Ivoyg91aXs0q6R5qUDqMSrFOficKrsn6f1v5GsLyXshDCNDE5V1zvaicJSEZaaPDPWVD6HZe8jlMCYUbXAib7Hb7g/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">北京轩竹康明生物科技<span style="color: black;">机构</span>总经理 <strong style="color: blue;"><span style="color: black;">朱晓东</span></strong><strong style="color: blue;"><span style="color: black;">博士</span></strong></span></strong><span style="color: black;"><span style="color: black;">分析了抗体编辑技术平台<span style="color: black;">药品</span>的<span style="color: black;">研发</span>策略</span>。其中，朱博士<span style="color: black;">说到</span>，双特异性抗体<span style="color: black;">药品</span><span style="color: black;">研发</span>难度的“Twin Peaks”<span style="color: black;">便是</span>科学和技术平台的挑战，<span style="color: black;">必须</span><span style="color: black;">大众</span>重新思考<span style="color: black;">怎样</span>实现协同效应或新功能、双抗新<span style="color: black;">功效</span>机制的<span style="color: black;">选取</span>策略、CMC的难度和成本、<span style="color: black;">身体</span>的稳定性和免疫原性等难点。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/Ivoyg91aXs0q6R5qUDqMSrFOficKrsn6fHslL56q89WatQ8RaQBZm8ricPM2IADjIet8gEnqqaSJBiazrufC2iaKew/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">北京轩义医药科技有限<span style="color: black;">机构</span>常务副总经理&nbsp;<strong style="color: blue;"><span style="color: black;">周海平</span></strong><strong style="color: blue;"><span style="color: black;">博士</span></strong></span></strong><span style="color: black;">以新型IL-2<span style="color: black;">药品</span><span style="color: black;">开发</span>等案例为切入点，向<span style="color: black;">大众</span>解析了基于结构的蛋白质<span style="color: black;">药品</span>设计。抗体优化的传统<span style="color: black;">办法</span>有着<span style="color: black;">很强</span>的库容、工作量大、表位可能漂移、成功率不高这些劣势。而CAD在抗体工程中的应用，能够有效起到优化的<span style="color: black;">功效</span>，使之<span style="color: black;">持有</span>库容小、目的性强、成功率高等优点。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/Ivoyg91aXs0q6R5qUDqMSrFOficKrsn6fkec5UIPRvGibtBAlXiclxBmHTcwIQpnBuR3icCXKXmdzic6Z4ZykeXD0Pw/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">近年，基于肿瘤微环境特异性激活的TCB技术交易<span style="color: black;">逐步</span>活跃，各大<span style="color: black;">公司</span>纷纷布局。肿瘤微环境特异性激活技术能够<span style="color: black;">明显</span><span style="color: black;">加强</span>治疗窗，可用于单抗，双抗，ADC，cytokine等新型生物<span style="color: black;">药品</span>的<span style="color: black;">研发</span>。</span><strong style="color: blue;"><span style="color: black;">浙江道尔生物科技有限<span style="color: black;">机构</span>CEO&nbsp;<strong style="color: blue;"><span style="color: black;">黄岩山博士</span></strong></span></strong><span style="color: black;">介绍，</span><span style="color: black;">基于肿瘤微环境特异性激活技术种类繁多，可能是<span style="color: black;">将来</span>bsAb <span style="color: black;">研发</span>双特异的一个<span style="color: black;">要紧</span>方向，<span style="color: black;">然则</span><span style="color: black;">日前</span>都尚<span style="color: black;">处在</span><span style="color: black;">初期</span><span style="color: black;">科研</span><span style="color: black;">周期</span>。<span style="color: black;">怎样</span><span style="color: black;">选取</span>合适的酶切位点，可能是肿瘤组织特异性<span style="color: black;">药品</span>设计的<span style="color: black;">重要</span>。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/Ivoyg91aXs0q6R5qUDqMSrFOficKrsn6fcmfFVwK5p8RsRCvGVeQWhX8EI9icEib3m4iaE8iajbgibARdCeyWcnaEbdw/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">米度（南京）生物技术有限<span style="color: black;">机构</span>副总经理 王璞</span></strong><span style="color: black;">针对放射性同位素技术在新药<span style="color: black;">开发</span>中的应用这一<span style="color: black;">专题</span>分享了经验与见解。米度（南京）生物技术有限<span style="color: black;">机构</span>是一家国内分子影像医药<span style="color: black;">开发</span>外包（MI-CRO）<span style="color: black;">公司</span>。米度生物利用放射标记（Radiolabeling）和分子影像（Molecular Imaging）技术，<span style="color: black;">能够</span>为海内外医药<span style="color: black;">公司</span>及科研院所<span style="color: black;">供给</span><span style="color: black;">药品</span>筛选、生物分布、药代动力学<span style="color: black;">科研</span>、药效学<span style="color: black;">评估</span>等新药<span style="color: black;">开发</span>整体<span style="color: black;">处理</span><span style="color: black;">方法</span>和外包技术服务。<span style="color: black;">同期</span>，米度生物针对放射性<span style="color: black;">药品</span><span style="color: black;">供给</span><span style="color: black;">包含</span><span style="color: black;">初期</span><span style="color: black;">研发</span>、CMC、临床前、临床及注册申报的一站式服务。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/Ivoyg91aXs0q6R5qUDqMSrFOficKrsn6flNmJzD6Q3Y43cYhibjSehR5SiblXpMrgwsGG4hckQImb5GuNY0h7IeHA/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">杭州翰思生物医药有限<span style="color: black;">机构</span>董事长&nbsp;<strong style="color: blue;"><span style="color: black;">张发明博士</span></strong></span></strong><span style="color: black;"><span style="color: black;"><span style="color: black;">分享了</span><span style="color: black;">翰思生物自主<span style="color: black;">开发</span>的抗&nbsp;PD-1/CD47双特异抗体新药&nbsp;HX009的案例等内容，</span></span>深入解析了肿瘤免疫双功能抗体的设计及临床<span style="color: black;">科研</span>方面的各项机会和挑战。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/Ivoyg91aXs0q6R5qUDqMSrFOficKrsn6fv7rFfttPVlCZ1icQ2wVokic54cZJTr3thGroekhrhnSl3BxUcG9TcG1Q/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">聚焦<strong style="color: blue;">新型抗体的<span style="color: black;">研发</span>策略探索</strong>的圆桌环节，由</span><strong style="color: blue;"><span style="color: black;">上海复宏汉霖转化医学高级副总裁&nbsp;<span style="color: black;">刘宁姝博士</span></span></strong><span style="color: black;"><span style="color: black;">、</span><strong style="color: blue;">启德医药科技（苏州）有限<span style="color: black;">机构</span><span style="color: black;">开发</span>副总裁 <span style="color: black;">时丽丽博士</span></strong><span style="color: black;">、</span><strong style="color: blue;">上海盖浦生物科技有限<span style="color: black;">机构</span>总经理&nbsp;<span style="color: black;">胡辉</span></strong><span style="color: black;">、</span><strong style="color: blue;"><span style="color: black;">没</span>锡智康弘义生物科技联席CEO&nbsp;<span style="color: black;">黑永疆博士</span></strong><span style="color: black;"><span style="color: black;">一起</span>参与讨论。</span></span></span></p><span style="color: black;"><strong style="color: blue;"><span style="color: black;">分会场：</span></strong></span><span style="color: black;"><strong style="color: blue;">NASH新药<span style="color: black;">研发</span></strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">新加坡HistoIndex<span style="color: black;">机构</span> &amp; 杭州筹图科技有限<span style="color: black;">机构</span>COO / CTO <span style="color: black;">滕霄</span></span><span style="color: black;">博士</span></strong><span style="color: black;">将计算机图像分析技术和<span style="color: black;">机构</span>特有的SHG/TPE<span style="color: black;">没</span>染色<span style="color: black;">影像</span>技术相结合应用于<span style="color: black;">疾患</span>发展<span style="color: black;">评估</span><span style="color: black;">尤其</span>是NASH新药<span style="color: black;">研发</span>的病理<span style="color: black;">评估</span>中。滕博士领导团队在NASH临床前的多个动物模型上做了深入<span style="color: black;">科研</span>和算法验证，<span style="color: black;">已然</span>参与完成几十家国际国内领先的生物医药<span style="color: black;">公司</span>、CRO<span style="color: black;">机构</span>及<span style="color: black;">研究</span><span style="color: black;">公司</span>主办的<span style="color: black;">关联</span><span style="color: black;">实验</span>，为这些<span style="color: black;">科研</span>单位的下一步计划<span style="color: black;">供给</span>了<span style="color: black;">有效</span>、客观及可重复的量化依据。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">应对非酒精性脂肪性肝病（NAFLD）发病率日益<span style="color: black;">增加</span>，而<span style="color: black;">做为</span>NAFLD的活动<span style="color: black;">发展</span>期，非酒精性脂肪性肝炎（NASH）<span style="color: black;">没</span>任何有效<span style="color: black;">干涉</span><span style="color: black;">办法</span>。</span><strong style="color: blue;"><span style="color: black;">复旦大学<span style="color: black;">基本</span>医学院&nbsp;<strong style="color: blue;"><span style="color: black;">吴健教授</span></strong></span></strong><span style="color: black;">课题组<span style="color: black;">长时间</span>致力于NASH<span style="color: black;">出现</span>、<span style="color: black;">发展</span>病理机制的<span style="color: black;">科研</span>，在<span style="color: black;">这次</span>大会上分享了<span style="color: black;">经过</span><span style="color: black;">控制</span>肝星状细胞GPR-91受体阻止非酒精性脂肪性肝炎纤维化<span style="color: black;">发展</span>。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">NASH<span style="color: black;">行业</span>有<span style="color: black;">知道</span>的未满足临床需求，近三年来<span style="color: black;">药品</span>治疗<span style="color: black;">开发</span>在<span style="color: black;">全世界</span>的竞争态势<span style="color: black;">显著</span>，对<span style="color: black;">科研</span>中心、<span style="color: black;">科研</span>者和<span style="color: black;">病人</span>群体的<span style="color: black;">需求</span>都<span style="color: black;">拥有</span><span style="color: black;">必定</span>挑战性。<strong style="color: blue;"><span style="color: black;">IQVIA 艾昆纬医学总监、大中华区医学非肿团队负责人</span><span style="color: black;">孙永馨博士</span></strong><span style="color: black;"><span style="color: black;">暗示</span>，IQVIA</span>在临床<span style="color: black;">实验</span>中<span style="color: black;">累积</span>的经验，结合数据资源与专业分析的<span style="color: black;">优良</span>，可<span style="color: black;">帮助</span>申办方完成<span style="color: black;">科研</span><span style="color: black;">方法</span>设计、中心筛选、<span style="color: black;">实验</span>高质量合规推进，并<span style="color: black;">处理</span>新药<span style="color: black;">开发</span>时效性等<span style="color: black;">重要</span>问题</span><span style="color: black;">。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">上海疆云医疗健康科技有限<span style="color: black;">机构</span>创始人&amp;CEO <span style="color: black;">梁威</span></span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">博士</span></strong></span>基于上海疆云ERβ激动剂治疗NASH项目与糖尿病肾脏<span style="color: black;">疾患</span><span style="color: black;">药品</span>研发项目，分享了在NASH新药靶点、治疗机理及<span style="color: black;">开发</span>策略上的见解。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">乙型肝炎<span style="color: black;">迄今</span><span style="color: black;">没</span>法治愈，保守估计至2030年，中国慢性乙型肝炎<span style="color: black;">关联</span>死亡人数预计将达1000万，直接或间接损失每年高达数千亿元。</span><span style="color: black;"><span style="color: black;">临床上将乙肝表面抗原转阴<span style="color: black;">做为</span>乙肝功能性治愈的指标。</span><strong style="color: blue;"><span style="color: black;">上海爱科百<span style="color: black;">出现</span>物医药VP/副总裁&nbsp;<strong style="color: blue;"><span style="color: black;">彭程</span></strong></span></strong><span style="color: black;"><strong style="color: blue;">博士</strong></span></span><span style="color: black;"><span style="color: black;">暗示</span>，<span style="color: black;">日前</span>市面上有核苷类和干扰素两类<span style="color: black;">药品</span>用于乙肝治疗，但疗效欠佳，仅有3%的病人能够乙肝治愈。<span style="color: black;">非常多</span>制药<span style="color: black;">机构</span>都在大力<span style="color: black;">开发</span>乙肝治愈的<span style="color: black;">药物</span>，并有不少<span style="color: black;">药品</span><span style="color: black;">处在</span>临床<span style="color: black;">科研</span><span style="color: black;">周期</span>，有望在短期内<span style="color: black;">提高</span>乙肝治疗效果。</span></span></p><span style="color: black;"><strong style="color: blue;"><span style="color: black;">分会场：</span></strong></span><span style="color: black;"><strong style="color: blue;">小分子创新<span style="color: black;">药品</span>前沿探索</strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">烨辉医药科技有限<span style="color: black;">机构</span>创始人&amp;CEO <span style="color: black;">华烨</span></span></strong><span style="color: black;"><strong style="color: blue;">博士</strong><span style="color: black;">从BTK<span style="color: black;">得到</span>性耐药、BTKi国内外<span style="color: black;">开发</span><span style="color: black;">状况</span>、可逆非共价结合的BTK BN102等内容出发，多维度、多<span style="color: black;">方向</span>地解析了第三代BTK<span style="color: black;">控制</span>剂。</span></span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">晶泰科技技术总监 <strong style="color: blue;"><span style="color: black;">张臣</span></strong></span></strong><span style="color: black;"><strong style="color: blue;">博士</strong><span style="color: black;">向行业同仁们介绍了AI技术创造<span style="color: black;">药品</span><span style="color: black;">开发</span>的新模式。晶泰科技（XtalPi）是一家以数字化和智能化驱动的人工智能（AI）<span style="color: black;">药品</span><span style="color: black;">开发</span>科技<span style="color: black;">机构</span>，基于量子<span style="color: black;">理学</span>、量子化学、人工智能与云计算技术，为<span style="color: black;">全世界</span>创新药企<span style="color: black;">供给</span>智能化<span style="color: black;">药品</span><span style="color: black;">开发</span>服务。</span></span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">苏州晶云医药<span style="color: black;">全世界</span>商务部负责人 <strong style="color: blue;"><span style="color: black;">陈岑</span></strong></span></strong><span style="color: black;"><strong style="color: blue;">博士</strong><span style="color: black;">从<span style="color: black;">药品</span>晶型<span style="color: black;">科研</span>的背景、<span style="color: black;">道理</span>、思路和<span style="color: black;">办法</span>出发，强调了晶型<span style="color: black;">科研</span>在新药<span style="color: black;">开发</span>中的<span style="color: black;">要紧</span>性。晶云<span style="color: black;">药品</span>向<span style="color: black;">全世界</span>药企<span style="color: black;">供给</span>专业化的<span style="color: black;">药品</span>晶型<span style="color: black;">开发</span><span style="color: black;">方法</span>，<span style="color: black;">帮忙</span>加速<span style="color: black;">药品</span><span style="color: black;">开发</span>，为<span style="color: black;">制品</span>质量<span style="color: black;">供给</span><span style="color: black;">靠谱</span>的技术<span style="color: black;">保证</span>。凭借专业高质的服务和快速的响应，晶云已与<span style="color: black;">全世界</span>超500家药企<span style="color: black;">创立</span>合作，为超1,000个新药化合物<span style="color: black;">供给</span>了专业的技术<span style="color: black;">方法</span>。</span></span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">天津尚德药缘科技股份有限<span style="color: black;">机构</span>/南开大学 CEO/教授 </span></strong><strong style="color: blue;"><span style="color: black;">陈悦博士</span></strong><span style="color: black;"><span style="color: black;">介绍了新结构候选<span style="color: black;">药品</span>ACT001，并<span style="color: black;">日前</span>已<span style="color: black;">得到</span><span style="color: black;">关联</span>发明专利授权13项，其中1项获美、日、欧等20多个国家的授权。ACT001能够进入脑部，并能够可逆地开放血脑屏障，<span style="color: black;">加强</span>其它抗癌<span style="color: black;">药品</span>入脑浓度。</span></span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">广州燃石医学检验所药企合作高级总监</span></strong><strong style="color: blue;"><span style="color: black;">茅新如</span></strong><span style="color: black;"><span style="color: black;">暗示</span>，基于燃石内部大数据库可实现中国人群基因组数据的个性化分析 ，综合临床<span style="color: black;">科研</span>项目经验、多维度<span style="color: black;">研究</span>合作成果以及文献<span style="color: black;">发布</span>数据为药企合作伙伴<span style="color: black;">供给</span>肿瘤基因组数据一站式<span style="color: black;">处理</span><span style="color: black;">方法</span>，加快<span style="color: black;">精细</span><span style="color: black;">药品</span>临床<span style="color: black;">科研</span>的<span style="color: black;">研发</span>速度，降低<span style="color: black;">药品</span><span style="color: black;">开发</span><span style="color: black;">危害</span>。从<span style="color: black;">药品</span>临床<span style="color: black;">科研</span>适应症<span style="color: black;">选取</span>，<span style="color: black;">病人</span>筛选与分层，到药物<span style="color: black;">功效</span>机制和治疗<span style="color: black;">潜能</span>的挖掘，再到临床<span style="color: black;">实验</span><span style="color: black;">科研</span>中心的<span style="color: black;">精细</span>定位，为药企合作伙伴<span style="color: black;">供给</span><span style="color: black;">有效</span>的生物标志物临床策略。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">睿诺医疗科技(上海)有限<span style="color: black;">机构</span>CMO </span></strong><strong style="color: blue;"><span style="color: black;">肖东</span></strong><strong style="color: blue;"><span style="color: black;">博士</span></strong><span style="color: black;">针对“To optimize the determination of biomarkers of acute kidney injury (AKI) promotes the development of new drugs for prevention/Therapy of AKI”这一<span style="color: black;">专题</span>，深度分享了个人的经验与见解。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">盛世泰科生物医药技术(苏州)有限<span style="color: black;">机构</span>化学高级副总经理 郝岩</span></strong><span style="color: black;">分享了糖尿病市场<span style="color: black;">状况</span>、糖代谢及其衍生<span style="color: black;">疾患</span>、<span style="color: black;">关联</span>靶点、盛世泰科在该<span style="color: black;">行业</span>的<span style="color: black;">优良</span>等内容。</span></span></p><span style="color: black;"><strong style="color: blue;"><span style="color: black;">分会场：</span></strong></span><span style="color: black;"><strong style="color: blue;">ADC<span style="color: black;">药品</span><span style="color: black;">研发</span></strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">石药集团，高级</span></strong><strong style="color: blue;"><span style="color: black;">医学总监 杨修诰</span></strong><span style="color: black;">从<span style="color: black;">已然</span>上市的或完成概念验证（POC）的ADC<span style="color: black;">药品</span>的临床<span style="color: black;">研发</span>历程分析抗体偶联<span style="color: black;">药品</span>在临床<span style="color: black;">研发</span>过程中的<span style="color: black;">重要</span>点。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">乐普生物科技股份有限<span style="color: black;">机构</span><span style="color: black;">开发</span>副总裁&nbsp;</span></strong><strong style="color: blue;"><span style="color: black;">李虎博士</span></strong><span style="color: black;">介绍了抗体偶联<span style="color: black;">药品</span>(ADC)的发展<span style="color: black;">状况</span>、ADC的<span style="color: black;">构成</span>部分及<span style="color: black;">功效</span>机理，并对临床前<span style="color: black;">研发</span>的关注点<span style="color: black;">包含</span>靶点的<span style="color: black;">选取</span>、小分子毒素的<span style="color: black;">选取</span>、成药性<span style="color: black;">评定</span>等进行探讨，以及分享了实体瘤的挑战和应对策略。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">百力司康生物医药（杭州）有限<span style="color: black;">机构</span><span style="color: black;">一起</span>创始人&amp;首席科学官&nbsp;<strong style="color: blue;"><span style="color: black;">周宇虹</span></strong></span></strong><strong style="color: blue;"><span style="color: black;">博士</span></strong><span style="color: black;">分享了Enhertu的成功背景下，针对ADC的下一代HER2创新的机会与挑战。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">苏州宜联生物医药有限<span style="color: black;">机构</span>COO <strong style="color: blue;"><span style="color: black;">肖亮</span></strong></span></strong><strong style="color: blue;"><span style="color: black;">博士</span></strong><span style="color: black;">解析了ADC<span style="color: black;">全世界</span><span style="color: black;">开发</span><span style="color: black;">发展</span>、国内<span style="color: black;">开发</span><span style="color: black;">发展</span>与<span style="color: black;">表率</span>技术和<span style="color: black;">全世界</span>ADC<span style="color: black;">开发</span>新方向等内容，为观众们<span style="color: black;">供给</span>了几点ADC<span style="color: black;">药品</span><span style="color: black;">研发</span>的前瞻思考。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">东曜药业有限<span style="color: black;">机构</span>ADC<span style="color: black;">开发</span>部负责人 <strong style="color: blue;"><span style="color: black;">黄鹏</span></strong></span></strong><strong style="color: blue;"><span style="color: black;">博士</span></strong><span style="color: black;">基于<span style="color: black;">东曜药业ADC的CMC一站式技术平台和</span>关于ADC<span style="color: black;">药品</span>TAA013的案例<span style="color: black;">科研</span>，围绕ADC的CMC<span style="color: black;">开发</span>挑战及策略分享了深刻的观点和经验。</span></span></p><span style="color: black;"><strong style="color: blue;"><span style="color: black;">分会场：</span></strong></span><span style="color: black;"><strong style="color: blue;">不可成药靶点</strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">上海美志医药科技有限<span style="color: black;">机构</span>CEO<strong style="color: blue;"><span style="color: black;">舒永志</span></strong></span></strong><strong style="color: blue;"><span style="color: black;">博士</span></strong><span style="color: black;">介绍了靶蛋白降解技术及其BTK降解剂MZ-001的<span style="color: black;">科研</span><span style="color: black;">发展</span>，分享了<span style="color: black;">口服高<span style="color: black;">选取</span>性</span>BTK降解剂抗B细胞淋巴瘤<span style="color: black;">科研</span>思路。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">上海宇道生物技术有限<span style="color: black;">机构</span>CEO&nbsp;<strong style="color: blue;"><span style="color: black;">沈倩诚</span></strong></span></strong><strong style="color: blue;"><span style="color: black;">博士</span></strong><span style="color: black;"><span style="color: black;">发布</span>了</span><span style="color: black;">变构机制<span style="color: black;">药品</span><span style="color: black;">研发</span>的机会与难点、<span style="color: black;">经过</span>计算平台赋能变构<span style="color: black;">药品</span><span style="color: black;">研发</span>经验以及变构<span style="color: black;">药品</span><span style="color: black;">研发</span>的若干实例。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">勤浩医药是一家专注于<span style="color: black;">全世界</span>领先的小分子抗肿瘤新药<span style="color: black;">研发</span>的生物科技<span style="color: black;">机构</span>。<strong style="color: blue;">勤浩医药（苏州）有限<span style="color: black;">机构</span>创始人&amp;CEO 王奎锋博士</strong>
      </span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">暗示</span>，<span style="color: black;">机构</span>1.0管线聚焦于RAS-MAPK信号通路，超过30%的肿瘤中存在这条信号通路过度激活。勤浩医药着力打造独具<span style="color: black;">特殊</span>的创新<span style="color: black;">药品</span><span style="color: black;">开发</span>体系，<span style="color: black;">创立</span>了基于结构生物学的构效关系<span style="color: black;">科研</span>平台，基于靶点<span style="color: black;">科研</span>的<span style="color: black;">初期</span><span style="color: black;">药品</span>筛选平台以及涵盖药效、代谢和安全性<span style="color: black;">科研</span>的临床前<span style="color: black;">评估</span>平台，形<span style="color: black;">成为了</span>以靶向抗肿瘤品种为核心的<span style="color: black;">制品</span>管线。</p>

    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">开拓药业副总裁&amp;新药<span style="color: black;">科研</span>院院长&nbsp;<span style="color: black;">马连东</span></span></strong><span style="color: black;"><strong style="color: blue;">博士</strong>针对“用蛋白降解技术靶向不可成药的致癌转录因子”这一<span style="color: black;">专题</span>深度分享了<span style="color: black;">开发</span>经验与见解。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">尽管肿瘤生物学家<span style="color: black;">已然</span>鉴定了数以百计的肿瘤驱动因子，迄今为止<span style="color: black;">仅有</span>极<span style="color: black;">少许</span>（5%<span style="color: black;">上下</span>）被成功<span style="color: black;">研发</span>了临床靶向<span style="color: black;">药品</span>，绝大部分被认为“不可成药（undruggable）”、“难以成药（difficult to drug）”或 “有待成药（yet to be drugged）”，<span style="color: black;">极重</span>限制了抗肿瘤靶向<span style="color: black;">药品</span><span style="color: black;">科研</span>。<strong style="color: blue;"><span style="color: black;">上海中医药大学交叉科学<span style="color: black;">科研</span>院<span style="color: black;">科研</span>员&amp;化学生物学<span style="color: black;">科研</span>中心<span style="color: black;">专家</span>&nbsp;</span></strong><strong style="color: blue;"><span style="color: black;">柯细松教授</span></strong><span style="color: black;"><span style="color: black;">这次</span></span>
      </span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">报告以Wnt信号通路<span style="color: black;">重要</span>蛋白β-catenin为例，从蛋白纯化、结构解析、翻译后修饰（PTM）/相互<span style="color: black;">功效</span>（PPI）以及AlphaFold等<span style="color: black;">方向</span>探讨常规靶向<span style="color: black;">药品</span><span style="color: black;">发掘</span>模式的局限性，并介绍本实验室针对“undruggable”靶标的<span style="color: black;">药品</span><span style="color: black;">发掘</span>新策略和<span style="color: black;">科研</span>实例，这些策略理论上适用于任意靶标蛋白。</p>

    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">聚焦PROTAC新技术加持，小分子<span style="color: black;">药品</span>新机遇的圆桌环节，由</span><strong style="color: blue;"><span style="color: black;">上海中医药大学交叉科学<span style="color: black;">科研</span>院<span style="color: black;">科研</span>员&amp;化学生物学<span style="color: black;">科研</span>中心<span style="color: black;">专家</span> <span style="color: black;">柯细松教授</span></span></strong><span style="color: black;"><span style="color: black;">、</span><strong style="color: blue;">勤浩医药（苏州）有限<span style="color: black;">机构</span>，创始人&amp;CEO&nbsp;<span style="color: black;">王奎锋博士</span></strong><span style="color: black;">、</span></span><strong style="color: blue;"><span style="color: black;">北京加科思新药<span style="color: black;">开发</span>有限<span style="color: black;">机构</span>化学副总裁&nbsp;<span style="color: black;">龙伟博士</span></span></strong><span style="color: black;">和</span><strong style="color: blue;"><span style="color: black;">上海美志医药科技有限<span style="color: black;">机构</span>CEO <strong style="color: blue;"><span style="color: black;">舒永志</span></strong></span></strong><strong style="color: blue;"><span style="color: black;">博士</span></strong><span style="color: black;"><span style="color: black;"><span style="color: black;">一起</span>参与讨论。</span></span></span></p><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">-<span style="color: black;">更加多</span>现场精彩扫码查看-</span><span style="color: black;"><strong style="color: blue;">PIC 2021</strong></span><span style="color: black;"><strong style="color: blue;">感谢多方支持</strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">长路漫漫，潜心磨砺，<span style="color: black;">更加多</span>会议邀您共话！</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">优惠报名倒计时！</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">历史最悠久免疫&amp;基因治疗品牌会议ING嘉宾及议程大公开</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">邀您11月初共聚上海</strong></p><a style="color: black;"><span style="color: black;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></span></a>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">点击<span style="color: black;">照片</span>查看<span style="color: black;">更加多</span>详情！</span></strong></span></span></p>

听听海 发表于 2024-8-23 19:37:57

你的留言真是温暖如春，让我感受到了无尽的支持与鼓励。

j8typz 发表于 2024-9-29 15:49:56

i免费外链发布平台 http://www.fok120.com/

查看完整版本: 会后报告 | PIC 2021 第二届药物研发热点技术与平台论坛圆满落幕